Biocon is an Indian biopharma company aiming to deliver costly insulin and biologics as affordable biosimilars (equivalent follow-on products). It is among the top three global players for rh-insulin and insulin glargine and has supplied over 9.2 billion doses of insulin worldwide. In the US it launched the first interchangeable biosimilar insulin glargine in 2021 and insulin aspart (Kirsty) in 2025, both FDA-approved. With Civica and California's CalRx it also works to sharply cut soaring US insulin prices.
B
NARRATIVE VALUE
Certainty
●●● high
●●● high
ABCDEFG
There is no confirmed −; independently verified + decide the position (B). No unreachable strike-through.= non-additive meter
As of: 2026-Q3Status: ActiveCeiling reason: No confirmed −
History2026-Q3BHistory grows each quarter
Biocon (Biocon Biologics): Delivering diabetes care through affordable insulin and biosimilars. The letter is B; certainty is high. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)
Main narrative
One person’s story (N1)
+ A single story
People who could not afford costly insulin and could not keep up diabetes treatment. When Biocon provides an equivalent biosimilar insulin far cheaper, they can access treatment. The benefit appears as a collective: among the top three global players for rh-insulin, it has supplied over 9.2 billion doses of insulin worldwide.
Source nature: Biocon Biologics / FDA / P1 First-party / independent (FDA). Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- Launching the first US interchangeable biosimilar insulins (glargine 2021, aspart 2025) and supplying affordable insulin with Civica and California's CalRx.P1 First-party / Biocon Biologics
− effects (confirmed)
- No confirmed −.
Watching (unconfirmed; not counted in the assessment)
- A listed, for-profit biopharma (main business is medicines on world markets)
- industry-wide quality/regulatory debates (including FDA inspection findings at some sites)
- US-market dependence.
Looking ahead (not included in the assessment)
- Widening access via biosimilars; maintaining quality and GMP compliance; effective price cuts in developing markets and the US; expanding to other biologics.
A second look
The plus is access to affordable insulin and biologics for people with diabetes (People), backed by 9.2 billion+ doses, a top-three global position, the first US interchangeable biosimilars and the CalRx partnership. But it is a listed, for-profit biopharma whose main business is selling medicines on world markets, with industry-wide quality and regulatory debates (including FDA inspection findings at some sites). Weighing the genuine, large-scale insulin-access plus, B/high.
Sources
+N1Biocon Biologics / FDA｜FDA approval of interchangeable insulin biosimilars｜2025｜🔗
+ effectBiocon Biologics｜Kirsty / Civica / CalRx affordable insulin｜2025｜🔗
How to read this assessment
A Independently verified +, with no confirmed −
B Leans +, with independent backing
C Mixed. A confirmed − sets the ceiling, or much is unverified
D A serious confirmed − sets the ceiling
E A serious − reaches the core of the organization
F Serious and systemic, with little redeeming +
G Only extreme cases
Out of scope An entity whose core purpose is illegal
On hold Independent evidence is scarce on both + and −
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the narrative an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top